Drug intelligence / Profile preview

BW-20829

Development stage: Phase 2
Lead developer: Novartis
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BW-20829 is an investigational small interfering RNA (siRNA) therapy designed to lower levels of lipoprotein (a) [Lp(a)], a genetically determined risk factor for cardiovascular disease. Developed by Argo Biopharma using its proprietary RADS (RNAi Advance Delivery System) platform, the drug is engineered for hepatic targeting to achieve potent and durable silencing of the *LPA* gene, which encodes the protein component of Lp(a). In early 2024, Novartis acquired an exclusive license for the global development and commercialization of BW-20829. The candidate is currently being evaluated in Phase 2b clinical trials for the treatment of adults with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD).

Targets

LPA (Lysophosphatidic acid)ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on BW-20829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-20829.

Explore the full profile